IL-23R Antibody (753317) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # FAB16861Z
Conjugate
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Monoclonal Rat IgG1 Clone # 753317
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant mouse IL-23 R
Gly24-Asp372
Accession # Q8K4B4
Gly24-Asp372
Accession # Q8K4B4
Specificity
Detects mouse IL-23 R in direct ELISAs.
Clonality
Monoclonal
Host
Rat
Isotype
IgG1
Applications for IL-23R Antibody (753317) [DyLight 755]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-23R
Long Name
Interleukin 23 Receptor
Alternate Names
IL-23 R, IL23R
Additional IL-23R Products
Product Documents for IL-23R Antibody (753317) [DyLight 755]
Product Specific Notices for IL-23R Antibody (753317) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...